Atea Pharmaceuticals, Inc. 8K

Atea Pharmaceuticals reported Q1 2026 financial results and a pipeline update, confirming on-track Phase 3 HCV trials, advancing its HEV candidate AT-587 toward Phase 1, and detailing higher R&D and lower G&A expenses with $256.0 million in cash and investments as of March 31, 2026.

On May 12, 2026, Atea Pharmaceuticals, Inc. reported its unaudited financial results for the first quarter ended March 31, 2026, and provided a business update highlighting progress in its clinical pipeline, including that its two global Phase 3 trials of the bemnifosbuvir/ruzasvir regimen for hepatitis C (C-BEYOND in North America and C-FORWARD outside North America) remain on track with topline data expected in mid-2026 and around year-end 2026, respectively, alongside encouraging preclinical data for its hepatitis E candidate AT-587, for which a Phase 1 trial is planned to start in mid-2026; the company ended the quarter with $256.0 million in cash, cash equivalents and marketable securities, increased R&D spend to $41.1 million driven by HCV Phase 3 and HEV preclinical activities, reduced G&A expenses to $6.9 million, and scheduled a conference call to discuss these developments.

Filing Facts

CIK

1593899

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-219507

Alert Tier

6